Condition: Relapsed/Refractory Immune Nephropathy · Relapsed/Refractory Immune-mediated Kidney Disease · Sponsor: Changhai Hospital
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
This description comes directly from the study's public registry record.
Zhiyong Guo, Dr · 86-021-31161406 · chguozhiyong@126.com
Always discuss trial participation with your own doctor first.
| Changhai Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07241468